$ACFN
ACORN ENERGY, INC.

2023 Q2 Form 10-Q Financial Statement

#000149315223016297 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $1.973M $1.749M $1.751M
YoY Change 21.71% -0.11% 2.7%
Cost Of Revenue $483.0K $433.0K $493.0K
YoY Change 28.8% -12.17% -0.4%
Gross Profit $1.490M $1.316M $1.258M
YoY Change 19.58% 4.61% 3.97%
Gross Profit Margin 75.52% 75.24% 71.84%
Selling, General & Admin $1.219M $1.197M $1.182M
YoY Change 1.16% 1.27% 17.5%
% of Gross Profit 81.81% 90.96% 93.96%
Research & Development $188.0K $214.0K $198.0K
YoY Change -11.32% 8.08% 11.24%
% of Gross Profit 12.62% 16.26% 15.74%
Depreciation & Amortization $38.00K $38.00K $20.00K
YoY Change 31.03% 90.0% 11.11%
% of Gross Profit 2.55% 2.89% 1.59%
Operating Expenses $1.407M $1.411M $1.380M
YoY Change -4.16% 2.25% 16.55%
Operating Profit $83.00K -$95.00K -$122.0K
YoY Change -137.39% -22.13% -569.23%
Interest Expense $16.00K $0.00
YoY Change -1700.0% -100.0%
% of Operating Profit 19.28%
Other Income/Expense, Net $11.00K
YoY Change
Pretax Income $99.00K -$84.00K -$122.0K
YoY Change -144.39% -31.15% -654.55%
Income Tax
% Of Pretax Income
Net Earnings $96.00K -$85.00K -$122.0K
YoY Change -143.05% -30.33% -654.55%
Net Earnings / Revenue 4.87% -4.86% -6.97%
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 -$3.099K
COMMON SHARES
Basic Shares Outstanding 39.76M shares 39.76M shares 39.69K shares
Diluted Shares Outstanding 39.78K shares 39.73K shares 39.69K shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.573M $1.346M $1.784M
YoY Change 24.94% -24.55% -9.63%
Cash & Equivalents $1.573M $1.346M $1.784M
Short-Term Investments
Other Short-Term Assets $398.0K $312.0K $1.059M
YoY Change 80.09% -70.54% 22.71%
Inventory $803.0K $804.0K $674.0K
Prepaid Expenses
Receivables $701.0K $771.0K $820.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $4.392M $4.131M $4.337M
YoY Change 14.46% -4.75% 16.37%
LONG-TERM ASSETS
Property, Plant & Equipment $614.0K $641.0K $1.030M
YoY Change -10.63% -37.77% 41.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $224.0K $211.0K $980.0K
YoY Change 25.84% -78.47% 57.3%
Total Long-Term Assets $1.817M $1.883M $2.010M
YoY Change -8.51% -6.32% 48.67%
TOTAL ASSETS
Total Short-Term Assets $4.392M $4.131M $4.337M
Total Long-Term Assets $1.817M $1.883M $2.010M
Total Assets $6.209M $6.014M $6.347M
YoY Change 6.63% -5.25% 24.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $321.0K $361.0K $516.0K
YoY Change -5.59% -30.04% 73.15%
Accrued Expenses $157.0K $137.0K $336.0K
YoY Change 0.64% -59.23% 15.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.781M $4.711M $4.539M
YoY Change 11.39% 3.79% 19.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $18.00K $18.00K $2.361M
YoY Change -99.21% -99.24% 33.84%
Total Long-Term Liabilities $2.391M $2.377M $2.361M
YoY Change 4.59% 0.68% 33.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.781M $4.711M $4.539M
Total Long-Term Liabilities $2.391M $2.377M $2.361M
Total Liabilities $7.172M $7.088M $6.908M
YoY Change 9.03% 2.61% 24.09%
SHAREHOLDERS EQUITY
Retained Earnings -$101.3M -$101.4M
YoY Change 0.27%
Common Stock $103.3M $103.3M
YoY Change 0.06%
Preferred Stock
YoY Change
Treasury Stock (at cost) $3.036M $3.036M
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity -$971.0K -$1.080M -$561.0K
YoY Change
Total Liabilities & Shareholders Equity $6.209M $6.014M $6.347M
YoY Change 6.63% -5.25% 24.97%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income $96.00K -$85.00K -$122.0K
YoY Change -143.05% -30.33% -654.55%
Depreciation, Depletion And Amortization $38.00K $38.00K $20.00K
YoY Change 31.03% 90.0% 11.11%
Cash From Operating Activities $238.0K -$83.00K $221.0K
YoY Change -157.35% -137.56% 225.0%
INVESTING ACTIVITIES
Capital Expenditures $11.00K $26.00K -$159.0K
YoY Change -110.0% -116.35% 1887.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$11.00K -$26.00K -$159.0K
YoY Change -90.0% -83.65% 1887.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $5.000K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities 238.0K -$83.00K 221.0K
Cash From Investing Activities -11.00K -$26.00K -159.0K
Cash From Financing Activities 0.000 $5.000K 0.000
Net Change In Cash 227.0K -$104.0K 62.00K
YoY Change -143.24% -267.74% -169.66%
FREE CASH FLOW
Cash From Operating Activities $238.0K -$83.00K $221.0K
Capital Expenditures $11.00K $26.00K -$159.0K
Free Cash Flow $227.0K -$109.0K $380.0K
YoY Change -174.43% -128.68% 400.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000880984
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
CY2023Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
usd
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
shares
CY2022Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
shares
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
shares
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-33886
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
ACORN ENERGY, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-2786081
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1000 N West
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1200
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Wilmington
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
DE
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19801
CY2023Q1 dei City Area Code
CityAreaCode
410
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
654-3315
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39757589 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1346000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1450000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
771000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
597000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
804000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
789000 usd
CY2023Q1 us-gaap Deferred Costs Current
DeferredCostsCurrent
898000 usd
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
887000 usd
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
312000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
288000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
4131000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
4011000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
641000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
653000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
272000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
298000 usd
CY2023Q1 us-gaap Deferred Costs
DeferredCosts
759000 usd
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
807000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
211000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
215000 usd
CY2023Q1 us-gaap Assets
Assets
6014000 usd
CY2022Q4 us-gaap Assets
Assets
5984000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
361000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
243000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
137000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
171000 usd
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4047000 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3984000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
118000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
116000 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
48000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
58000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4711000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4572000 usd
CY2023Q1 us-gaap Deferred Revenue
DeferredRevenue
2169000 usd
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
2187000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-122000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
190000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
220000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
16000 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2377000 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2423000 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
42000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
42000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39757589 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39757589 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39722589 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39722589 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
397000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
397000 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
102911000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
102889000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101352000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101267000 usd
CY2023Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
801920 shares
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
801920 shares
CY2023Q1 us-gaap Treasury Stock Value
TreasuryStockValue
3036000 usd
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
3036000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1080000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1017000 usd
CY2023Q1 us-gaap Minority Interest
MinorityInterest
6000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
6000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1074000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1011000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6014000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5984000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1749000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1751000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
433000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
493000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
1316000 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
1258000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
214000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
198000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1197000 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1182000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
1411000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
1380000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-95000 usd
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
11000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-84000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-122000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-84000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-122000 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1000 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-85000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-123000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39734 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39688 shares
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1011000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-84000 usd
CY2023Q1 ACFN Stock Issued During Period Value Stock Warrant Exercised
StockIssuedDuringPeriodValueStockWarrantExercised
5000 usd
CY2023Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
1000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1074000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1074000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-461000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-122000 usd
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
1000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-553000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-553000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-84000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-122000 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
38000 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
20000 usd
CY2023Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
3000 usd
CY2023Q1 ACFN Noncash Lease Expense
NoncashLeaseExpense
31000 usd
CY2022Q1 ACFN Noncash Lease Expense
NoncashLeaseExpense
29000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
17000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
31000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
174000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-56000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
18000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
57000 usd
CY2023Q1 ACFN Increase Decrease In Deferred Cost Of Goods Sold
IncreaseDecreaseInDeferredCostOfGoodsSold
-37000 usd
CY2022Q1 ACFN Increase Decrease In Deferred Cost Of Goods Sold
IncreaseDecreaseInDeferredCostOfGoodsSold
135000 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
20000 usd
CY2022Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-7000 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
45000 usd
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
299000 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-33000 usd
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-30000 usd
CY2023Q1 ACFN Increase Decrease In Other Current Liabilities And Noncurrent Liabilities
IncreaseDecreaseInOtherCurrentLiabilitiesAndNoncurrentLiabilities
-75000 usd
CY2022Q1 ACFN Increase Decrease In Other Current Liabilities And Noncurrent Liabilities
IncreaseDecreaseInOtherCurrentLiabilitiesAndNoncurrentLiabilities
-123000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-83000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
221000 usd
CY2023Q1 us-gaap Payments For Software
PaymentsForSoftware
26000 usd
CY2022Q1 us-gaap Payments For Software
PaymentsForSoftware
157000 usd
CY2022Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
2000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-159000 usd
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-104000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
62000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1450000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1722000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1346000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1784000 usd
CY2023Q1 ACFN Accrued Preferred Dividends
AccruedPreferredDividends
1000 usd
CY2022Q1 ACFN Accrued Preferred Dividends
AccruedPreferredDividends
1000 usd
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_804_eus-gaap--NatureOfOperations_zBHZkrnNHJX2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1— <span id="xdx_82C_zBe5vvjXI7j2">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements of Acorn Energy, Inc. and its subsidiaries, OmniMetrix, LLC and OMX Holdings, Inc. (collectively, “Acorn” or “the Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete consolidated financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-month periods ended March 31, 2023 and 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. All dollar amounts are rounded to the nearest thousand and, thus, are approximate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 16, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84D_eus-gaap--UseOfEstimates_zZF7MYmpXPKi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zPO9Qn7SrZKh">Use of Estimates in Preparation of Financial Statements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the unaudited condensed unaudited consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As applicable to these unaudited condensed consolidated financial statements, the most significant estimates and assumptions relate to uncertainties with respect to income taxes, inventories, account receivable allowances, contingencies, revenue recognition, management’s projections and analyses of the possible impairments.</span></p>
CY2023Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zXmWr7fHby4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zpqvJgVZsA63" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_863_zeAv5whORyEl">Concentrations of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and trade accounts receivable. The Company’s cash was deposited with a U.S. bank and amounted to $<span id="xdx_902_eus-gaap--DepositAssets_iI_c20230331_z16h9Y3VdWQc">1,346,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">at March 31, 2023. The Company does not believe there is a significant risk of non-performance by these counterparties. For the three-month periods ended March 31, 2023 and 2022, there were no customers that represented greater than <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--ProductOrServiceAxis__custom--OneCustomerMember_zaMKpdYYG6Jj">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">% of the Company’s total invoiced sales.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--ProductOrServiceAxis__custom--OneCustomerMember_zBaiUnO78Oc9">21</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the accounts receivable at March 31, 2023 was due from one customer who pays its receivables over usual credit periods. Approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--ProductOrServiceAxis__custom--OneCustomerMember_zMpBqaC1DNIk">12%</span> of the accounts receivable at December 31, 2022 was due from one customer who pays its receivables over usual credit periods. As of May 9, 2023, we have collected 100% of the full outstanding amount of $<span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--ProductOrServiceAxis__custom--OneCustomerMember_zOhItjVn7DZf">160,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, in the aggregate, due from the one customer as of March 31, 2023. <span style="background-color: white">Credit risk with respect to the balance of trade receivables is generally diversified due to the number of entities comprising the Company’s customer base.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Deposit Assets
DepositAssets
1346000 usd
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
3000 usd
CY2022Q1 us-gaap Inventory Write Down
InventoryWriteDown
0 usd
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1035000 shares
CY2023Q1 ACFN Weighted Average Exercise Price Of Options And Warrants
WeightedAverageExercisePriceOfOptionsAndWarrants
0.41 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
964000 shares
CY2022Q1 ACFN Weighted Average Exercise Price Of Options And Warrants
WeightedAverageExercisePriceOfOptionsAndWarrants
0.40 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-85000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-123000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39734 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39688 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39734 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39688 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2022 us-gaap Financing Receivable Allowance For Credit Losses Period Increase Decrease
FinancingReceivableAllowanceForCreditLossesPeriodIncreaseDecrease
-1000 usd
CY2023Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
5000 usd
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
10000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1346000 usd
CY2023Q1 ACFN Working Capital
WorkingCapital
-580000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1346000 usd
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4047000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-104000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-83000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5000 usd
CY2023Q2 us-gaap Cash
Cash
1543000 usd
CY2023Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
776000 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
5000 usd
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
10000 usd
CY2021Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6000 usd
CY2023Q1 us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
2000 usd
CY2022 us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
3000 usd
CY2023Q1 us-gaap Financing Receivable Allowance For Credit Losses Period Increase Decrease
FinancingReceivableAllowanceForCreditLossesPeriodIncreaseDecrease
7000 usd
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
716000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
684000 usd
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
88000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
105000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
804000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
789000 usd
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
6000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
4000 usd
CY2023Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.045 pure
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
308000 usd
CY2023Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.045 pure
CY2023Q1 ACFN Cash Paid For Operating Lease Liabilities
CashPaidForOperatingLeaseLiabilities
31000 usd
CY2022Q1 ACFN Cash Paid For Operating Lease Liabilities
CashPaidForOperatingLeaseLiabilities
30000 usd
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y5M26D
CY2023Q1 ACFN Share Based Compensation Arrangement By Share Based Payment Award Fair Value Options Grants In Period Issued
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOptionsGrantsInPeriodIssued
25000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
129000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
129000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
67000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
325000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
17000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
308000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
118000 usd
CY2021Q3 us-gaap Sublease Income
SubleaseIncome
2375 usd
CY2021Q3 ACFN Estimated Sublease Payments
EstimatedSubleasePayments
6100 usd
CY2021Q3 ACFN Annual Service Cost
AnnualServiceCost
2220 usd
CY2023Q1 ACFN Finance Lease Liability Sublease Payments Due Next Twelve Months
FinanceLeaseLiabilitySubleasePaymentsDueNextTwelveMonths
28000 usd
CY2023Q1 ACFN Finance Lease Liability Sublease Payments Due Year Two
FinanceLeaseLiabilitySubleasePaymentsDueYearTwo
28000 usd
CY2023Q1 ACFN Finance Lease Liability Sublease Payments Due Year Three
FinanceLeaseLiabilitySubleasePaymentsDueYearThree
14000 usd
CY2023Q1 ACFN Finance Lease Liability Sublease Payments Due
FinanceLeaseLiabilitySubleasePaymentsDue
70000 usd
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39757589 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
943790 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.42
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y3M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16000 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
105000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.34
CY2023Q1 ACFN Share Based Compensation Arrangement By Share Based Payment Award Option Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresAndExpirationsInPeriod
-13834 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.40
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1034956 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.41
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y4M24D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
27000 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
858008 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.41
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y10M24D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
24000 usd
CY2023Q1 ACFN Fair Value Of Options Granted
FairValueOfOptionsGranted
25000 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0390 pure
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.950 pure
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
40000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1749000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
1316000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
38000 usd
CY2023Q1 ACFN Segment Income Loss Before Income Taxes
SegmentIncomeLossBeforeIncomeTaxes
151000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1751000 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
1258000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20000 usd
CY2022Q1 ACFN Segment Income Loss Before Income Taxes
SegmentIncomeLossBeforeIncomeTaxes
168000 usd
CY2023Q1 ACFN Net Income Loss Before Income Taxes For Reportable Segments
NetIncomeLossBeforeIncomeTaxesForReportableSegments
151000 usd
CY2022Q1 ACFN Net Income Loss Before Income Taxes For Reportable Segments
NetIncomeLossBeforeIncomeTaxesForReportableSegments
168000 usd
CY2023Q1 ACFN Unallocated Cost Of Corporate Headquarters
UnallocatedCostOfCorporateHeadquarters
235000 usd
CY2022Q1 ACFN Unallocated Cost Of Corporate Headquarters
UnallocatedCostOfCorporateHeadquarters
290000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-84000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-122000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1749000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1751000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
6171000 usd
CY2023Q1 ACFN Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
1654000 usd
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-1609000 usd
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
6216000 usd
CY2023Q1 ACFN Contract With Customer Liability Revenue Additions In Year One
ContractWithCustomerLiabilityRevenueAdditionsInYearOne
4047000 usd
CY2023Q1 ACFN Contract With Customer Liability Revenue Additions In Year Two
ContractWithCustomerLiabilityRevenueAdditionsInYearTwo
1762000 usd
CY2023Q1 ACFN Contract With Customer Liability Revenue Additions In Year Three
ContractWithCustomerLiabilityRevenueAdditionsInYearThree
407000 usd
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
6216000 usd
CY2022Q4 us-gaap Deferred Sales Inducements Net
DeferredSalesInducementsNet
1694000 usd
CY2023Q1 ACFN Contract With Customer Liability Additions Net Of Adjustments
ContractWithCustomerLiabilityAdditionsNetOfAdjustments
231000 usd
CY2023Q1 ACFN Contract With Customer Liability Sales Recognized
ContractWithCustomerLiabilitySalesRecognized
-268000 usd
CY2023Q1 us-gaap Deferred Sales Inducements Net
DeferredSalesInducementsNet
1657000 usd
CY2023Q1 ACFN Contract With Customer Liability Recognized Cost Of Sales In Year One
ContractWithCustomerLiabilityRecognizedCostOfSalesInYearOne
898000 usd
CY2023Q1 ACFN Contract With Customer Liability Recognized Cost Of Sales In Year Two
ContractWithCustomerLiabilityRecognizedCostOfSalesInYearTwo
583000 usd
CY2023Q1 ACFN Contract With Customer Liability Recognized Cost Of Sales In Year Three
ContractWithCustomerLiabilityRecognizedCostOfSalesInYearThree
176000 usd
CY2023Q1 ACFN Contract With Customer Liability Recognized Cost Of Sales
ContractWithCustomerLiabilityRecognizedCostOfSales
1657000 usd
CY2022Q4 ACFN Contract With Customer Asset Sale Commission
ContractWithCustomerAssetSaleCommission
399000 usd
CY2023Q1 ACFN Contract With Customer Asset Additions
ContractWithCustomerAssetAdditions
57000 usd
CY2023Q1 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
55000 usd
CY2023Q1 ACFN Contract With Customer Asset Sale Commission
ContractWithCustomerAssetSaleCommission
401000 usd
CY2023Q1 ACFN Contract With Customer Liability Sales Commissions Expense In Year One
ContractWithCustomerLiabilitySalesCommissionsExpenseInYearOne
203000 usd
CY2023Q1 ACFN Contract With Customer Liability Sales Commissions Expense In Year Two
ContractWithCustomerLiabilitySalesCommissionsExpenseInYearTwo
137000 usd
CY2023Q1 ACFN Contract With Customer Liability Sales Commissions Expense In Year Three
ContractWithCustomerLiabilitySalesCommissionsExpenseInYearThree
61000 usd
CY2023Q1 ACFN Contract With Customer Liability Sales Commissions Expense
ContractWithCustomerLiabilitySalesCommissionsExpense
401000 usd

Files In Submission

Name View Source Status
0001493152-23-016297-index-headers.html Edgar Link pending
0001493152-23-016297-index.html Edgar Link pending
0001493152-23-016297.txt Edgar Link pending
0001493152-23-016297-xbrl.zip Edgar Link pending
acfn-20230331.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
acfn-20230331_lab.xml Edgar Link unprocessable
acfn-20230331_def.xml Edgar Link unprocessable
acfn-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
acfn-20230331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending